| 1.4 -0.02 (-1.41%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.72 | 1-year : | 1.86 |
| Resists | First : | 1.47 | Second : | 1.6 |
| Pivot price | 1.38 |
|||
| Supports | First : | 1.27 | Second : | 1.06 |
| MAs | MA(5) : | 1.38 |
MA(20) : | 1.39  |
| MA(100) : | 1.38 |
MA(250) : | 1.32 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 63.3 |
D(3) : | 55.9 |
| RSI | RSI(14): 49 |
|||
| 52-week | High : | 1.87 | Low : | 0.83 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PGEN ] has closed below upper band by 42.3%. Bollinger Bands are 38.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.41 - 1.42 | 1.42 - 1.42 |
| Low: | 1.35 - 1.36 | 1.36 - 1.37 |
| Close: | 1.39 - 1.4 | 1.4 - 1.41 |
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Wed, 24 Apr 2024
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse ... - InvestorsObserver
Tue, 19 Mar 2024
Precigen Inc (PGEN) Reports Full Year 2023 Financial Results - GuruFocus.com
Tue, 19 Mar 2024
Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript - Seeking Alpha
Tue, 19 Mar 2024
Precigen Reports Full Year 2023 Financial Results and Business Updates - PR Newswire
Fri, 08 Mar 2024
Precigen, Inc.'s (NASDAQ:PGEN) top owners are private equity firms with 38% stake, while 30% is held by institutions - Yahoo Finance
Tue, 05 Mar 2024
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 249 (M) |
| Held by Insiders | 1.2248e+008 (%) |
| Held by Institutions | 11.7 (%) |
| Shares Short | 17,270 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.225e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 904.6 % |
| Return on Equity (ttm) | -30.3 % |
| Qtrly Rev. Growth | 6.22e+006 % |
| Gross Profit (p.s.) | -17.12 |
| Sales Per Share | -44.28 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -67 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -1.7 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 5.16 |
| Dividend | 0 |
| Forward Dividend | 1.69e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|